DTE Announces Appointment of Diego Areces as CEO
16.9.2021 08:00:00 EEST | Business Wire | Press release
The Board of DTE ehf. (DTE) (www.dte.ai), a leader in metals intelligence, is pleased to announce the appointment of Diego Areces as Chief Executive Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915006176/en/
Diego Areces, CEO of DTE (Photo: Business Wire)
Diego Areces, who joined DTE in 2020 after a long tenure at Schneider Electric, succeeds Karl Matthiasson, one of the Company's two founders, who steps into the role of Chief Financial Officer.
The changes reflect DTE's increased commercial focus and reorganization to accelerate its market expansion, as it continues to innovate around its unique elemental analysis LP-LIBS™ technology, advances its real-time and predictive metals intelligence platform to the next level, and launches its forthcoming Series B financing round. Diego Areces' mission will be to lead DTE through its growth phase, while Karl Matthiasson, in his new role as CFO, will focus on solidifying DTE's financial foundation, expanding its global presence and leading the next funding round.
“I'm very pleased to take on the CEO role to continue building on the success of DTE’s technological accomplishments,” commented Mr. Areces. “Our disruptive technology is poised to transform the metals market and the team has developed solid relationships with strategic customers, which collectively form the launch pad of DTE's market expansion. Our metals intelligence platform enabled by our unique elemental analysis technology allows us to deliver beneficial financial and environmental business outcomes to our customers. We see ourselves as significant contributors to a carbon-neutral future and digital transformation towards Industry 4.0 for the industries we serve. I want to thank both Karl and Sveinn, the co-founders and prior CEOs, for their achievements and the support that they have provided to my appointment.”
“We’re delighted to announce Diego’s leadership and are convinced that he is the right person to drive DTE going forward,” commented DTE co-founder and CEO Karl Matthiasson. “We look forward to the next phase of the Company’s evolution and will continue to build a larger, stronger team to deliver the value that we can achieve through unlocking the future of metals.”
Richard MacKellar, Managing Partner at Chrysalix Ventures and Chairman of the Board of DTE, commented, “Chrysalix is excited and supportive of the nomination of Diego Areces as DTE's CEO. We welcome Diego to this new role in the Company as we continue to drive DTE's growth to fulfill its potential in leading a market of new and better, greener, safer, more efficient metals through technological innovation and value-added solutions. I would also like to thank and acknowledge Karl for his outstanding leadership up to this point, which continues with the challenge of leading DTE's financing and next funding rounds.”
Find out more about DTE's metals intelligence solutions at www.dte.ai.
About DTE ehf.
DTE, Unlocking the Future of Metals™, is the leading innovator in real-time intelligence from liquid metals, serving customers across the metals production and manufacturing value chain through maximizing value, sustainability, safety, and efficiency for all stakeholders.
Our purpose is advancing human progress with greener, safer, more efficient, and more valuable metals, contributing to the 1.5-degree challenge while driving its digital transformation towards Industry 4.0 with the next generation of IIoT analysis technology. DTE provides tangible financial and environmental business outcomes from the plant floor to the business levels through valuable intelligence and predictive insights from liquid metals.
IREAS, DTE's unique, connected, real-time intelligence from liquid metals solution seamless integrated IT and OT, combining chemical composition analysis from molten metals based on Liquid-Phase Laser-Induced Breakdown Spectroscopy (LP-LIBS™) with an artificial intelligence-based analytics platform and digital metals intelligence services.
For more information, please visit www.dte.ai.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915006176/en/
Contact information
DTE ehf.
Diego Areces, CEO
diego.areces@dte.ai
(+354) 698 0173
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 11:15:00 EEST | Press release
Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easier to access, navigate and manage. This will ultimately give pet parents better guidance, greater confidence and more control at every point in
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom